Regencell Bioscience Holdings Limited Overview
Pro stress-test →Regencell Bioscience is an early-stage bioscience company focused on research, development, and commercialization of Traditional Chinese Medicine (TCM) for treating neurocognitive disorders, specifically ADHD and autism spectrum disorder (ASD). The company has generated massive stock price appreciation despite having no reported revenue, experiencing over 59,000% gains in 2025.
Strategic Profile
Pro stress-test →Regencell is positioning itself at the intersection of traditional Chinese medicine and neurocognitive treatment, developing standardized TCM formulae for mild, moderate, and severe ADHD and ASD patients. The company operates with a lean structure of 10 employees and is backed by a non-profit foundation established in 2017 that provides assistance to children with ADHD/ASD and elderly people with dementia.
Competitive Landscape
Pro stress-test →Regencell operates in a niche segment of neurocognitive disorder treatment using TCM, with limited direct competitors in this specific approach. Broader competitors include traditional pharmaceutical ADHD treatments and other biotech companies developing novel neurocognitive therapies, though the TCM-focused approach is relatively differentiated. The company faces competitive pressure from established pharmaceutical companies with FDA-approved ADHD medications.
Industry Context
Regencell Bioscience Holdings Limited operates in Biopharmaceutical/Biotech - Neurocognitive Disorder Treatment.
Key facts
Founded: 2014 · Headquarters: Causeway Bay, Hong Kong · Employees: 10 · Revenue: $0 · Market cap: $17.56B